ATLANTA, Nov. 30 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., President and Chief Executive Officer, will present a company overview and update at the Lazard Life Sciences Conference on Wednesday, December 1, 2004, at 9:00 a.m. ET at the Mandarin Oriental Hotel in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO )
Interested parties can access a live audio webcast of the presentation at the company’s Investor Relations website at http://www.atherogenics.com/ , under the “Investor Calendar” tab. A replay of the presentation will be available for 14 days.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics’ lead compound, AGI-1067, is being evaluated in the pivotal Phase III clinical trial called ARISE, as an oral therapy for the treatment of atherosclerosis. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Fujisawa. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma using its novel vascular protectant(TM) technology. For more information about AtheroGenics, please visit http://www.atherogenics.com/ .
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about clinical trial results, our future results of operations or our financial condition, research, development and commercialization of our product candidates, anticipated trends in our business, and other risks that could cause actual results to differ materially. These risks are discussed in AtheroGenics’ Securities and Exchange Commission filings, including but not limited to the risks discussed in AtheroGenics’ Form 10-K for fiscal 2003 and our Quarterly Report on Form 10-Q for the third quarter of 2004.
Photo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comAtheroGenics, Inc.
CONTACT: Donna Glasky, Corporate Communications of AtheroGenics, Inc.,+1-678-336-2517, or investor@atherogenics.com ; or Investor Relations, LilianStern of Stern Investor Relations, +1-212-362-1200, or lilian@sternir.com ; orMedia Relations, Katie Brazel of Fleishman Hillard, +1-404-739-0150, orbrazelk@fleishman.com
Web site: http://www.atherogenics.com/
